Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Pittsburgh, PA
NPI: 1013988021Primary Practice Location
UPMC PRESBYTERIAN SHADYSIDE
3459 5th Ave, Pittsburgh, PA
Primary Employer
Oncology Hematology Association Inc
upmc.edu
HQ Phone
Get David's Phone Numberphone_androidMobile
Get David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
PA State Medical License
1991 - 2026
American Board of Internal Medicine
Medical Oncology
University of Pennsylvania Health System
Fellowship • Hematology and Medical Oncology
1992 - 1994
Presbyterian Medical Center of the University of Pennsylvania Health System
Residency • Internal Medicine
1989 - 1992
University of Maryland School of Medicine - Baltimore
medschool.umaryland.edu
Medical School
Until 1989
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 91 | 275 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 65 | 134 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 25 | 32 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 16 | 28 |
Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
Authors: Athanassios Argiris, Ahmad Tarhini, Chandra Belani
Journal: Clin Cancer Res
Publication Date: 2010-11-02
Phase II study of docetaxel (D) and oxaliplatin (O) in recurrent metastatic transitional cell cancer (mTCC) of the urothelial tract.
Authors: Leonard Appleman
Publication Date: 2012-02
Small-cell lung cancer: a perspective on the past and a preview of the future.
Authors: Comis, R L, Friedland, D M, Good, B C
Journal: Oncology (Williston Park)
Lead Sponsor: David A. Clump, MD, PhD
Intervention / Treatment: DRUG: Capecitabine, DRUG: Gemcitabine, RADIATION: Stereotactic Body Radiation Therapy (SBRT)
Lead Sponsor: Roswell Park Cancer Institute
Collaborators: University of Pittsburgh
Intervention / Treatment: BIOLOGICAL: androgen ablation (AA), BIOLOGICAL: DC1 vaccine
Lead Sponsor: Eastern Cooperative Oncology Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: carboxyamidotriazole
